Related Experiment Videos
Differential inactivation of caspase-8 in lung cancers
Narayan Shivapurkar1, Shinichi Toyooka, Michael T Eby
1Hamon Center for Therapeutic Oncology Research, Departments of Pathology, University of Texas Southwestern Medical Center, 6000 Harry Hines Boulevard, Dallas, Texas 75390-8593, USA.
Abstract:
Caspase-8 (CASP8) is an apoptosis inducing cysteine protease which is activated through the formation of a death-inducing signaling complex when death receptors are complexed to their specific ligands. Recent reports indicate that CASP8 expression is lost via a combination of promoter methylation and allelic loss in subset of neuroblastomas. We investigated the state of the gene in lung tumors and cell lines. RT-PCR studies indicated that gene expression was lost in most (27 of 34, 79%) of small cell lung carcinoma (SCLC) cell lines, but expression was retained in all 22 non-SCLC (NSCLC) lines tested. Loss of gene expression at the RNA level was associated with absent protein expression by Western blotting and lack of CASP8 enzymatic activity. Methylation of the promoter region of the CASP8 gene was present in 16 of 27 (59%) of the SCLC lines lacking gene expression. All methylated cell lines lacked the presence of an unmethylated allele indicating biallelic methylation or loss of non-methylated allele. Promoter methylation was absent in all SCLC and NSCLC cell lines retaining gene expression, and all of these lines had the unmethylated form of the gene. One non-expressing SCLC cell line, NCI-H82, had a homozygous deletion at 2q33 encompassing the chromosomal location of the CASP8 gene. The mechanism of gene inactivation in the remaining 10 of 27 (37%) non-expressing SCLC cell lines is unknown. Using five polymorphic markers for 2q33 a high frequency of allelic loss was present in SCLC lines. Analyses of fresh tumors showed that 15 of 43 (35%) of the SCLC, seven of 40 (18%) of bronchial carcinoids and none of 44 NSCLC tumors had CASP8 promoter methylation. Because only approximately 60% of SCLC cell lines lacking CASP8 expression were methylated, extrapolating from the cell line data, we estimate that approximately 58% of SCLC and 30% of bronchial carcinoids lack CASP8 expression. Thus, CASP8 expression is absent in a subset of both high grade (SCLC) and low grade (carcinoid) neuroendocrine lung tumors but not in NSCLC, which usually lack neuroendocrine features. CASP8 may function as a tumor suppressor gene in neuroendocrine lung tumors.
Insights
Caspase-8 (CASP8) expression is frequently lost in small cell lung carcinoma (SCLC) and carcinoid tumors due to promoter methylation or gene deletion. This loss is not observed in non-small cell lung carcinoma (NSCLC).
Area of Science:
- Molecular Biology
- Oncology
- Genetics
Background:
- Caspase-8 (CASP8) is a key protease in apoptosis, activated by death receptor signaling.
- Loss of CASP8 expression has been reported in neuroblastomas via promoter methylation and allelic loss.
Purpose of the Study:
- To investigate the status of CASP8 gene expression and its inactivation mechanisms in lung tumors and cell lines.
- To determine if CASP8 functions as a tumor suppressor in neuroendocrine lung tumors.
Main Methods:
- Reverse transcription-polymerase chain reaction (RT-PCR) to assess gene expression.
- Western blotting for protein expression analysis.
- Analysis of promoter methylation and allelic loss using polymorphic markers.
Main Results:
- CASP8 expression was lost in 79% of small cell lung carcinoma (SCLC) cell lines but retained in all non-SCLC (NSCLC) lines.
- Promoter methylation was found in 59% of SCLC lines lacking expression, often with biallelic methylation or allele loss.
- CASP8 promoter methylation was present in 35% of SCLC tumors and 18% of bronchial carcinoid tumors, but not in NSCLC tumors.
Conclusions:
- CASP8 expression is frequently lost in SCLC and carcinoid tumors, suggesting a role as a tumor suppressor gene in these neuroendocrine lung cancers.
- Inactivation mechanisms include promoter methylation and potentially gene deletion, but are not observed in NSCLC.
- The findings highlight CASP8 as a potential therapeutic target in neuroendocrine lung tumors.